Abstract |
Serum aldolase B levels were determined in patients with malignant tumors using a radioimmunoassay method. Thirty-one of 52 patients with malignant tumors had decreased serum aldolase B levels of less than 20 ng/ml, whereas almost all of the normal subjects and the patients with liver diseases and other benign diseases showed serum aldolase B levels of more than 20 ng/ml. The decreased aldolase B levels observed in cancer patients were unrelated to the clinical stage of their disease. The decrease of aldolase B correlated well with the decrease of fructose-1-phosphate (F1P)-aldolase activity, but not with fructose-1,6-diphosphate ( FDP)- aldolase activity in the sera of cancer patients. Mixing experiments did not identify an inhibitor of aldolase B in sera of cancer patients. Furthermore, recovery of serum aldolase B levels after successful surgical resection in cancer patients suggested that the low levels of aldolase B in sera of cancer patients was not of genetic origin. The mechanism responsible for the decrease of aldolase B in sera of cancer patients is unclear.
|
Authors | M Asaka, T Kimura, S Nishikawa, T Miyazuki, E Alpert |
Journal | Cancer
(Cancer)
Vol. 62
Issue 12
Pg. 2554-7
(Dec 15 1988)
ISSN: 0008-543X [Print] United States |
PMID | 3191454
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Isoenzymes
- Fructose-Bisphosphate Aldolase
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Female
- Fructose-Bisphosphate Aldolase
(blood)
- Humans
- Isoenzymes
(blood)
- Liver Diseases
(enzymology)
- Male
- Middle Aged
- Neoplasms
(blood, enzymology)
- Radioimmunoassay
- Stomach Neoplasms
(blood, enzymology)
|